Osteoporosis, a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration, is a significant public health concern. With the aging population, the prevalence of osteoporosis is expected to increase. This article provides an overview of the advancements in the management of osteoporosis, focusing on recent therapeutic options and diagnostic tools.
New imaging techniques have revolutionized the diagnosis of osteoporosis. High-resolution peripheral quantitative computed tomography (HR-pQCT) provides detailed images of the bone microarchitecture, enhancing the prediction of fracture risk. Trabecular bone score (TBS), a texture parameter that evaluates pixel grey-level variations in lumbar spine dual-energy X-ray absorptiometry (DXA) images, is another promising tool that provides additional information about bone quality.
Recent years have witnessed the emergence of novel pharmacological treatments. Anti-sclerostin antibodies, such as romosozumab, increase bone formation and decrease bone resorption, showing a significant reduction in vertebral and non-vertebral fractures. Anabolic agents like Teriparatide and Abaloparatide stimulate bone formation, offering another therapeutic avenue. Moreover, Denosumab, a RANKL inhibitor, has demonstrated superior efficacy in increasing bone mineral density (BMD) and reducing fracture risk.
Non-pharmacological interventions remain integral to osteoporosis management. These include lifestyle modifications such as adequate calcium and vitamin D intake, regular weight-bearing exercise, smoking cessation, and limiting alcohol intake. Furthermore, fall prevention strategies are vital in reducing fracture risk in this population.
The landscape of osteoporosis management is rapidly evolving, with advancements in both diagnostic tools and therapeutic options. These innovations promise a more comprehensive and personalized approach to osteoporosis care. Healthcare professionals need to stay updated with these advancements to optimize patient outcomes and reduce the burden of this debilitating disease.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation